



NEWS RELEASE

# Arcus Biosciences to Participate at Upcoming Investor Conferences

9/1/2021

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming September 2021 virtual investor conferences.

- Citi's 16th Annual Virtual Biopharma Conference, Friday, September 10 at 1:25 pm ET
- 2021 Cantor Virtual Global Healthcare Conference, Monday, September 27 at 4:40 pm ET

A live audio webcast of the presentation will be available by visiting the "Investors" section of the Arcus website at [www.arcusbio.com](http://www.arcusbio.com). A replay of the webcast will be available for at least two weeks following the live event.

## About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development: **Etrumadenant (AB928)**, the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, and non-small cell lung. **Quemliclustat (AB680)**, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development in combination with zimberelimab and gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. **Domvanalimab (AB154)**, an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study evaluating zimberelimab monotherapy, domvanalimab plus zimberelimab and domvanalimab plus etrumadenant plus zimberelimab for first-line

treatment of PD-L1  $\geq$  50% metastatic non-small cell lung cancer (NSCLC). In addition, domvanalimab has advanced into ARC-10, Arcus's "two in one trial" to support the potential approvals of both zimberelimab and zimberelimab plus domvanalimab and is expected to advance into a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage 3 NSCLC setting later this year. **AB308**, an anti-TIGIT antibody that is FcR-enabled, is in clinical development, with a potential focus on hematological malignancies. **Zimberelimab (AB122)**, Arcus's anti-PD-1 monoclonal antibody, is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit [www.arcusbio.com](http://www.arcusbio.com).

Source: Arcus Biosciences

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210901005903/en/): <https://www.businesswire.com/news/home/20210901005903/en/>

### Investor Inquiries:

Katherine Bock

VP Investor Relations & Corporate Strategy

(510) 694-6231

[kbock@arcusbio.com](mailto:kbock@arcusbio.com)

### Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

[hkolkey@arcusbio.com](mailto:hkolkey@arcusbio.com)

Source: Arcus Biosciences